Novartis submits Exjade iron chelator
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Novartis submits its iron chelator Exjade (deferasirox, formerly ICL670) May 3 for treatment of chronic iron overload due to blood transfusions. The firm is touting the agent's once-daily dosing and oral route of administration as advantages over standard treatment, which requires a daily infusion that can take several hours. Novartis markets another iron chelating agent, Desferal (deferoxamine), which is administered via transfusion. The company reported during its Jan. 20 R&D update that Exjade missed its primary endpoint of non-inferiority to Desferal in a pivotal study, noting that the finding could impact timing or labeling (1Pharmaceutical Approvals Monthly February 2005, p. 3). The NDA was submitted within the firm's projected first-half 2005 timeframe...
You may also be interested in...
Novartis Plans Three NME Filings In 2005, Including First Oral VEGF Inhibitor
Novartis plans three NME filings in 2005, including first oral VEGF agent, firm says during Jan. 20 R&D day. PTK787 has blockbuster potential in colorectal cancer, Novartis says. Nine more NME filings are scheduled for next two years
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.